AbbVie le Genmab A/S kajeno ba phatlalalitse liphetho tsa mantlha tsa sehlopha sa pele sa EPCORE™ NHL-1 phase 1/2 teko ea tleliniki e hlahlobang epcoritamab (DuoBody®-CD3xCD20), e leng antibody ea lipatlisiso e ka tlase ho bispecific. Sehlopha sa thuto se kenyelletsa bakuli ba 157 ba nang le bokooa bo boholo ba B-cell lymphoma (LBCL) ba ileng ba fumana bonyane mela e 'meli ea pele ea phekolo ea tsamaiso, ho kenyelletsa le karolo ea 38.9 e ileng ea fumana phekolo ea pele ka chimeric antigen receptor (CAR) T-cell therapy. Ho ipapisitsoe le liphetho tsa mantlha, lik'hamphani li tla ikopanya le balaoli ba taolo ea lefats'e.

LBCL ke mofuta o hōlang ka potlako oa non-Hodgkin's lymphoma (NHL) - mofetše o hlahang tsamaisong ea lymphatic - e amang B-cell lymphocyte, mofuta oa sele e tšoeu ea mali. Ho hakanngoa hore ho na le linyeoe tse ncha tsa 150,000 tsa LBCL selemo se seng le se seng lefatšeng ka bophara. LBCL e kenyelletsa diffuse e kholo ea B-cell lymphoma (DLBCL), e leng mofuta o tloaelehileng ka ho fetisisa oa NHL lefatšeng ka bophara 'me o nka karolo ea 31 lekholong ea linyeoe tsohle tsa NHL.1,2,3,4

"Re ikemiselitse ho ntlafatsa tsebo e matla ea mofets'e oa mali oa AbbVie ho nts'etsapele epcoritamab, hammoho le Genmab, bakeng sa bakuli ba bang ba mofetše oa mali ba nang le khetho e fokolang ea kalafo," ho boletse Mohamed Zaki, MD, Ph.D., motlatsi oa mopresidente le hlooho, nts'etsopele ea lefats'e ea oncology. AbbVie.

Liphetho tsa mantlha tse tsoang sehlopheng sena li bonts'itse sekhahla se netefalitsoeng sa karabelo (ORR) sa liperesente tse 63.1 ke komiti e ikemetseng ea tlhahlobo (IRC). Nako ea karabelo e bonoang (DOR) e bile likhoeli tse 12. Mela e bolelang ea phekolo ea pele sehlopheng sena e ne e le 3.5 (2 ho ea ho mela e 11 ea phekolo). Liketsahalo tse mpe ka ho fetisisa tse hlahang kalafo ea sehlopha leha e le sefe (tse kholo ho feta kapa tse lekanang le karolo ea 20 lekholong) li kenyelletsa cytokine release syndrome (CRS) (49.7%), pyrexia (23.6 lekholong), mokhathala (22.9 lekholong), neutropenia (21.7 lekholong), le letšollo (liperesente tse 20.4). Liketsahalo tse mpe tse hlahang sehlopheng sa 3 kapa 4 (tse kholo ho feta kapa tse lekanang le karolo ea 5 lekholong) li kenyelletsa neutropenia (karolo ea 14.6 lekholong), phokolo ea mali (karolo ea 10.2 lekholong), palo ea neutrophil e fokotsehile (karolo ea 6.4 lekholong), le thrombocytopenia (karolo ea 5.7 lekholong). Ho feta moo, CRS e hlokometsoeng ea Kereiti ea 3 e ne e le liperesente tse 2.5. Lintlha li tla romelloa bakeng sa ho hlahisoa kopanong ea bongaka e tlang.

Epcoritamab e ntse e ntlafatsoa ke AbbVie le Genmab e le karolo ea tšebelisano e pharaletseng ea lik'hamphani tsa oncology. Likhamphani li ntse li ikemiselitse ho hlahloba epcoritamab e le monotherapy, 'me ka ho kopana, ho pholletsa le mekhoa ea phekolo bakeng sa mefuta e sa tšoaneng ea malignancies, ho kenyelletsa le karolo e tsoelang pele ea 3, letlapa le bulehileng, teko e sa tloaelehang e hlahlobang epcoritamab e le monotherapy ho bakuli ba nang le DLBCL e khutletseng hape / e hanyetsang. (NCT: 04628494).

"Mmoho le molekane oa rona, AbbVie, re tla sebetsa le balaoli ba taolo ho fumana mehato e latelang le ho tsoela pele ho lekola epcoritamab litekong tse fapaneng tsa kliniki e le khetho e ka bang teng ea kalafo bakeng sa bakuli ba nang le mafu a fapaneng a mali," ho boletse Jan van de Winkel, Ph. D., molaoli ea ka sehloohong, Genmab. "Re labalabela ho arolelana liphuputso kopanong ea bongaka e tlang."

SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:

The companies remain committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy for a variety of hematologic malignancies, including an ongoing phase 3, open-label, randomized trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory DLBCL (NCT.
LBCL is a fast-growing type of non-Hodgkin’s lymphoma (NHL) – a cancer that develops in the lymphatic system – that affects B-cell lymphocytes, a type of white blood cell.
“Together with our partner, AbbVie, we will work with regulatory authorities to determine next steps and continue to evaluate epcoritamab in a variety of clinical trials as a potential treatment option for patients with various hematological malignancies,”.